Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661. Treatment with the investigational compound showed increased bone mineral density, increased osteoblast activity and decreased osteoclast activity. Aaron Mulivor, Ph.D. from Acceleron presented these data at the 3rd Joint Meeting of the European Calcified Tissue Society & the International Bone and Mineral Society in Athens, Greece, 7-11 May 2011.